NCT02545127View on ClinicalTrials.gov

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
Preterm DeliveryInadequate Milk Production
Interventions
DRUG

Merotocin

Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).

DRUG

Placebo

Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).

Trial Locations (10)

10595

Ferring Investigational Site, Valhalla

21201

Ferring Investigational Site, Baltimore

27610

Ferring Investigational Site, Raleigh

29425

Ferring Investigational Site, Charleston

45229

Ferring Investigational Site, Cincinnati

46601

Ferring Investigational Site, South Bend

77030

Ferring Investigational Site, Houston

78229

Ferring Investigational Site, San Antonio

06520

Ferring Investigational Site, New Haven

02115

Ferring Investigational Site, Boston

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY